Amphetamine Toxicity

Sarayu Vasan; Brian Murray; Garth  Olango

Amphetamine Toxicity

Earn CME/CE in your profession:

Free Review Questions

Continuing Education Activity

Amphetamine abuse remains prevalent in the United States (US), with significant implications for public health and individual well-being. The ramifications of amphetamine toxicity and overdose are profound, contributing to substantial morbidity and mortality rates. Notably, amphetamines' sympathomimetic properties precipitate adverse cardiovascular and neurological effects, with studies indicating their involvement in a significant proportion of drug-related deaths in the US. Symptoms of amphetamine toxicity span a spectrum, encompassing tachycardia, hypertension, impulsivity, aggression, serotonin syndrome, psychosis, and seizures, underscoring the complexity of its clinical manifestations.

In this course, participants explore the multifaceted management of amphetamine toxicity. The dynamics of both acute and chronic amphetamine use and their profound impacts on cardiovascular, neurological, and psychiatric systems are discussed. Recognizing symptoms of amphetamine toxicity, such as tachycardia, hypertension, and serotonin syndrome, while recognizing the limitations of relying solely on drug metabolite testing for diagnosis, is also explored. Furthermore, collaboration and communication among interprofessional teams are emphasized, as this enhances patient outcomes by leveraging the expertise of diverse healthcare professionals.

Objectives:

Differentiate between acute and chronic effects of amphetamine use to tailor appropriate management strategies.
Interpret laboratory and radiologic findings to confirm amphetamine toxicity and rule out alternative diagnoses.
Screen patients for amphetamine use disorders and assess their risk of toxicity based on history and clinical presentation.
Communicate effectively with interdisciplinary teams to coordinate comprehensive care for patients with amphetamine toxicity.

Introduction

Amphetamine abuse is widespread and associated with a significant impact on cardiovascular and neurological systems in overdose. In many parts of the world, amphetamines have been an abused class of drugs since the 1930s. Methamphetamine (METH) and its derivative, 3,4-methylenedioxymethamphetamine (MDMA), are extensively abused drugs, and the acute effects of these drugs include increased alertness, hyperthermia, decreased appetite, and euphoria. However, long-term abuse can result in neurotoxicity and psychosis. Amphetamines increase the neurotransmission of dopamine (DA), serotonin (5-HT), and norepinephrine (NE) by entering neurons via the 5-HT and DA transporters and displacing storage vesicles. MDMA has a greater affinity for 5-HT transporters, causing an increased release of 5-HT. The clinical effects of amphetamine overdose are significant and usually observed in emergency departments.[1][2][3]

Etiology

Amphetamine use, both acute and chronic, may lead to amphetamine toxicity. Amphetamine use has increased steadily over time.[4] The reasons for the increased use of amphetamines are numerous, including a sustained desire for favorable drug effects like euphoria, mood elevation, and appetite suppression, the availability of amphetamine compounds as both legal and illegal substances, an increase in the production of amphetamines for sale in the illegal drug trade, and the affordability of illicit amphetamines as compared to other illicit drugs.[4] Recently, stress and anxiety related to the COVID-19 pandemic may have also contributed to increased amphetamine use.[5] Amphetamine dependence is not a prerequisite for toxicity, but those who become dependent on amphetamines may be at higher risk of experiencing it. Dependence is likely due to increased tolerance to amphetamine effects and the requirement of escalating doses to achieve the desired effect.

Epidemiology

In 2021, it was estimated that 36 million people used amphetamines across the globe. The majority of amphetamine users (55%) are men. For people undergoing treatment for drug use disorders, amphetamines are the primary drug of abuse 18% of the time in the Americas and 42% of the time in Asia.[United Nations Office of Drugs and Crime World Drug Report, 2023] The 2023 "Monitoring the Future Survey" estimated that 2.1% of adolescents in the US used illicit amphetamines.[Monitoring the Future National Survey Results on Drug Use, 1975-2023] Additionally, an estimated 1.8 million Americans 12 years and older have a methamphetamine use disorder.[SAMHSA NSDUH, 2022]

Pathophysiology

Amphetamines are structural analogs of the neurotransmitter phenethylamine (see Image. Phenethylamine Chemical Structure and Image. Amphetamine Chemical Structure), which regulates monoamine neurotransmission through the modulation of the trace amine-associated receptor 1 (TAAR1) and inhibition of the vesicular monoamine transporter 2 (VMAT2). TAAR1 is expressed in multiple locations within the central nervous system (CNS), including the dorsal and ventral caudate nucleus, putamen, substantia nigra, nucleus accumbens, ventral tegmental area, locus ceruleus, amygdala, and raphe nucleus.[6] Many of these areas play important roles in the development of addiction. Thus, the use of amphetamines begets the desire to continue using amphetamines.

The effects of TAAR1 agonism may extend beyond the central nervous system. Downstream effects from receptor activation may lead to increased reactive oxygen species, mitochondrial dysfunction, and alterations in intracellular calcium. These metabolic abnormalities have been implicated in the accelerated development of cardiovascular disease.[7][8][9] Amphetamines also cause necrotizing vasculitis of small- and medium-sized blood vessels, which can yield a myriad of end-organ complications (strokes and neurodegenerative diseases, coronary artery disease, ischemic bowel disease). The underlying etiology is not well understood and may result from the amphetamines or potential adulterants or contaminants.[10][11][12][13][14]

Toxicokinetics

Amphetamine has an oral bioavailability of about 75%. Peak plasma concentrations are found approximately 3 hours after ingestion. Peak cardiovascular effects occur approximately 1 hour after ingestion, while behavioral changes are seen around 2 hours after ingestion.[15] No ceiling effect has been noted.[16] However, these effects are relatively short-lived, owing to a rapid decline in monoamine release after peak concentrations are reached. Amphetamine is hepatically metabolized by multiple enzymes, including (cytochrome) CYP2D6, dopamine β-hydroxylase, and flavin-containing monooxygenase-3.[17] Only 30% to 40% of amphetamine is eliminated as an unchanged drug in the urine. An acidic urine pH traps amphetamine in the renal tubules and decreases its elimination half-life.[18]

Methamphetamine can be ingested orally, insufflated nasally, smoked, or injected intravenously. Bioavailability is reliable (~70% or greater) with these ingestion routes. Peak serum concentrations of methamphetamine occur approximately 3 to 6 hours after oral ingestion. Nasal insufflation leads to a peak serum concentration in 5 to 10 minutes, and smoking leads to peak serum concentrations within 5 minutes. Methamphetamine is more lipophilic than amphetamine and is less prone to metabolism by monoamine oxidase. Methamphetamine is hepatically metabolized and renally eliminated, similarly to amphetamine.

History and Physical

Amphetamines are used for fatigue, appetite suppression, and narcolepsy treatment. Patients experiencing amphetamine toxicity thus often present with anorexia, dehydration, weight loss, and insomnia. Patients may be highly agitated, even to the point of risking the safety of healthcare staff and themselves. Patients should be asked what drug(s) they used, the route of administration they utilized, and the duration of their drug use. Blood pressure, heart rate, and other vital signs should be taken immediately upon presentation. The physical examination should include assessments for hyperthermia, evidence of end-organ damage (eg, neurological deficits, respiratory compromise, or new cardiac murmurs), and skin ulcerations or abscesses.

Evaluation

When patients appear intoxicated and have symptoms consistent with amphetamine toxicity, testing for metabolites of amphetamine can be useful to confirm a diagnosis of the condition. However, ingestion of some amphetamines, including 3,4-methylenedioxymethamphetamine, will not reliably result in a positive test for the presence of amphetamines.[19][20] Conversely, some non-amphetamine medications may cause false-positive results for the presence of amphetamines. These drugs include pseudoephedrine,[21] mebeverine,[22] metoprolol,[23] tetracaine,[24] dimethylamylamine,[25] aripiprazole,[26] and ranitidine.[27] Thus, clinicians should not rely on drug metabolite testing alone to make a diagnosis of amphetamine toxicity. Obtaining an accurate medication history for the patient may allow a diagnosis to be made independently of drug metabolite testing. Therefore, obtaining medication histories should always be a focus during the evaluation of patients who are intoxicated.

Additionally, laboratory and radiologic evaluation for patients with suspected amphetamine toxicity should focus on confirming that the toxic effects of amphetamines are present and ruling out other causes for them. Dehydration and hyponatremia may be confirmed with a basic metabolic panel. An electrocardiogram, chest x-ray, and troponin test are necessary to assess the presence of coronary ischemia, including myocardial infarction and aortic dissection. Computed tomography of the head is also useful to assess hemorrhagic stroke as a potential cause of neurologic deficits. Finally, obtaining serum creatine kinase and lactic acid levels may help identify muscle damage and tissue ischemia related to tonic-clonic seizures, myoclonus, or hyperthermia.

Treatment / Management

Treating amphetamine toxicity is supportive. There are no specific antidotes for amphetamine or amphetamine-like compounds. Therefore, treatment should focus on symptom and complication management. Patients with agitation should be treated with parenteral benzodiazepines. Diazepam is an ideal choice if intravenous access is available; otherwise, intramuscular lorazepam or midazolam is appropriate. If the patient presents with hyperactive delirium, benzodiazepines should be avoided, and an intramuscular dose of ketamine at 4-5 mg/kg may be used to stabilize the patient's agitation.

Patients who present with delirium may benefit from adjunctive treatment with a dopamine antagonist, like haloperidol. However, while the dopamine blockade can help treat the psychiatric and psychomotor disorders associated with amphetamine toxicity, these agents may cause harm. They can decrease the seizure threshold,[28] cause extrapyramidal side effects, increase heat production by altering thermoregulatory function,[29][30][31] and prolong the QTc interval. Thus, judicious and cautious use of these agents in the setting of amphetamine toxicity is required.

Hypertension related to amphetamine toxicity may abate with agitation treatment. However, some patients may require antihypertensive treatment to combat hypertensive urgency or emergency. Peripheral vasodilators like nitroglycerin and nicardipine may be effective in lowering blood pressure. Beta-blockers should not be used as sole antihypertensive therapies as their use may lead to unopposed α-adrenergic tone and a worsened hypertensive state. Similarly to hypertension, hyperthermia may abate with the treatment of agitation. However, external cooling with ice baths, misting, or cooled IV fluids may also be required to achieve euthermia. External cooling therapies should be rapidly administered when patients present with temperatures exceeding 107 °F.

Seizures should initially be treated with parenteral benzodiazepines. Barbiturates and propofol may be added for further seizure control. Phenytoin, fosphenytoin, and valproic acid should be avoided due to their ineffectiveness in aborting toxicologic seizures. There are no approved treatments for amphetamine use disorder. Naltrexone has been evaluated for this indication based on its ability to decrease the effects of the dopamine reward system. Some studies have shown promising results for naltrexone.[32][33] In contrast, others have shown a lack of appreciable effects on cravings or amphetamine use.[34][35][36] However, many of these studies were conducted on animals. There is an overall paucity of high-quality data from human subjects to base conclusions on naltrexone's efficacy. As a result, consultation with an addiction specialist, cognitive behavioral therapy, and group therapy remain the primary means to treat amphetamine use disorder.

Differential Diagnosis

To diagnose amphetamine toxicity, other toxicities need to be explored, including toxicities to cocaine, methylxanthine, phencyclidine, and other sympathomimetics. Neurocognitive disorders and stroke should also be ruled out. Schizophrenia, mania, alcohol withdrawal, and meningitis should also be considered.

Complications

Clinicians should screen patients experiencing amphetamine toxicity for complications related to the sympathetic surge that accompanies it. These complications include hemorrhagic strokes,[37][38][39] seizures,[40] hyperthermia,[41][42] serotonin syndrome, acute coronary syndrome,[43][44], cardiomyopathy,[45][46] cardiac valvulopathies,[47][48] aortic dissection,[49][50] rhabdomyolysis,[51] dehydration, acute kidney injury, arrhythmias, and hyponatremia.[52] Additionally, amphetamine toxicity may result in widespread vasospasm. These widespread vasospastic effects can cause ischemia anywhere in the body, including the bowel.[53][54][55][56] Lastly, amphetamine intoxication may be associated with psychosis, paranoid delusions, and hallucinations that resemble schizophrenia.[57][58][59]

Patients who chronically use amphetamines have an increased risk of developing pulmonary hypertension,[60][61][62] heart failure, and embolic strokes. Additionally, patients who chronically use amphetamines often have poor nutritional status, [63][64] oral hygiene, and widespread skin lesions.[65][66] Frequently, skin lesions result from delusions parasitosis, or Ekbom syndrome, where patients pick at their skin to remove imaginary insects.[67] Chronic use of amphetamines can also cause choreoathetoid movements, which can persist from weeks to years after cessation of amphetamine use.[68][69]

Deterrence and Patient Education

When treating a patient with an amphetamine use disorder, it is important to first medically stabilize them and then discuss the complications associated with use and ascertain their readiness for help and treatment. If they desire treatment and sobriety, they should be connected to an outpatient clinic that can provide further management.

Enhancing Healthcare Team Outcomes

Physicians, advanced practitioners, nurses, pharmacists, and other healthcare professionals play critical roles in managing amphetamine toxicity. They must accurately identify symptoms, assess severity, and differentiate toxicity from other conditions, utilizing comprehensive evaluations and medication histories. Effective communication and collaboration among team members facilitate coordinated care, ensuring patient safety and optimized outcomes. Clinicians must also apply evidence-based strategies in symptom management and complication prevention, utilizing supportive care approaches. Continuous evaluation and improvement of interventions enhance patient-centered care, promoting a holistic approach to addressing amphetamine abuse and associated toxicities.

(Click Image to Enlarge)

Amphetamine Chemical Structure. The illustration describes the structure of the stimulant amphetamine.

Public Domain via Wikimedia Commons

(Click Image to Enlarge)

Structure of amphetamine.
creative commons license

Details

References

[1]

Limanaqi F, Gambardella S, Biagioni F, Busceti CL, Fornai F. Epigenetic Effects Induced by Methamphetamine and Methamphetamine-Dependent Oxidative Stress. Oxidative medicine and cellular longevity. 2018:2018():4982453. doi: 10.1155/2018/4982453. Epub 2018 Jul 22 [PubMed PMID: 30140365]

Level 2 (mid-level) evidence

[2]

Kronstrand R, Guerrieri D, Vikingsson S, Wohlfarth A, Gréen H. Fatal Poisonings Associated with New Psychoactive Substances. Handbook of experimental pharmacology. 2018:252():495-541. doi: 10.1007/164_2018_110. Epub [PubMed PMID: 30105471]

[3]

Simmler LD, Liechti ME. Pharmacology of MDMA- and Amphetamine-Like New Psychoactive Substances. Handbook of experimental pharmacology. 2018:252():143-164. doi: 10.1007/164_2018_113. Epub [PubMed PMID: 29633178]

[4]

Courtney KE, Ray LA. Methamphetamine: an update on epidemiology, pharmacology, clinical phenomenology, and treatment literature. Drug and alcohol dependence. 2014 Oct 1:143():11-21. doi: 10.1016/j.drugalcdep.2014.08.003. Epub 2014 Aug 17 [PubMed PMID: 25176528]

[5]

Mellos E, Paparrigopoulos T. Substance use during the COVID-19 pandemic: What is really happening? Psychiatrike = Psychiatriki. 2022 Mar 28:33(1):17-20. doi: 10.22365/jpsych.2022.072. Epub 2022 Feb 21 [PubMed PMID: 35255473]

[6]

Cisneros IE, Ghorpade A. Methamphetamine and HIV-1-induced neurotoxicity: role of trace amine associated receptor 1 cAMP signaling in astrocytes. Neuropharmacology. 2014 Oct:85():499-507. doi: 10.1016/j.neuropharm.2014.06.011. Epub 2014 Jun 17 [PubMed PMID: 24950453]

[7]

Kevil CG, Goeders NE, Woolard MD, Bhuiyan MS, Dominic P, Kolluru GK, Arnold CL, Traylor JG, Orr AW. Methamphetamine Use and Cardiovascular Disease. Arteriosclerosis, thrombosis, and vascular biology. 2019 Sep:39(9):1739-1746. doi: 10.1161/ATVBAHA.119.312461. Epub 2019 Aug 21 [PubMed PMID: 31433698]

[8]

Tobolski J, Sawyer DB, Song SJ, Afari ME. Cardiovascular disease associated with methamphetamine use: a review. Heart failure reviews. 2022 Nov:27(6):2059-2065. doi: 10.1007/s10741-022-10261-7. Epub 2022 Jul 18 [PubMed PMID: 35844009]

[9]

Indave BI, Sordo L, Bravo MJ, Sarasa-Renedo A, Fernández-Balbuena S, De la Fuente L, Sonego M, Barrio G. Risk of stroke in prescription and other amphetamine-type stimulants use: A systematic review. Drug and alcohol review. 2018 Jan:37(1):56-69. doi: 10.1111/dar.12559. Epub 2017 May 8 [PubMed PMID: 28485090]

Level 1 (high-level) evidence

[10]

Citron BP, Halpern M, McCarron M, Lundberg GD, McCormick R, Pincus IJ, Tatter D, Haverback BJ. Necrotizing angiitis associated with drug abuse. The New England journal of medicine. 1970 Nov 5:283(19):1003-11 [PubMed PMID: 4394271]

[11]

Syed RH, Moore TL. Methylphenidate and dextroamphetamine-induced peripheral vasculopathy. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases. 2008 Feb:14(1):30-3. doi: 10.1097/RHU.0b013e3181639aaa. Epub [PubMed PMID: 18431096]

[12]

Loewenhardt B, Bernhard M, Pierskalla A, Neumann-Haefelin T, Hofmann E. Neurointerventional treatment of amphetamine-induced acute occlusion of the middle cerebral artery by intracranial balloon angioplasty. Clinical neuroradiology. 2013 Jun:23(2):137-43. doi: 10.1007/s00062-011-0122-1. Epub 2011 Dec 16 [PubMed PMID: 22173373]

[13]

Leithäuser B, Langheinrich AC, Rau WS, Tillmanns H, Matthias FR. A 22-year-old woman with lower limb arteriopathy. Buerger's disease, or methamphetamine- or cannabis-induced arteritis? Heart and vessels. 2005 Feb:20(1):39-43 [PubMed PMID: 15700202]

[14]

Bostwick DG. Amphetamine induced cerebral vasculitis. Human pathology. 1981 Nov:12(11):1031-3 [PubMed PMID: 7319490]

[15]

Angrist B, Corwin J, Bartlik B, Cooper T. Early pharmacokinetics and clinical effects of oral D-amphetamine in normal subjects. Biological psychiatry. 1987 Nov:22(11):1357-68 [PubMed PMID: 3663788]

[16]

Heal DJ, Smith SL, Gosden J, Nutt DJ. Amphetamine, past and present--a pharmacological and clinical perspective. Journal of psychopharmacology (Oxford, England). 2013 Jun:27(6):479-96. doi: 10.1177/0269881113482532. Epub 2013 Mar 28 [PubMed PMID: 23539642]

Level 3 (low-level) evidence

[17]

Santagati NA, Ferrara G, Marrazzo A, Ronsisvalle G. Simultaneous determination of amphetamine and one of its metabolites by HPLC with electrochemical detection. Journal of pharmaceutical and biomedical analysis. 2002 Sep 5:30(2):247-55 [PubMed PMID: 12191709]

[18]

Brams M, Mao AR, Doyle RL. Onset of efficacy of long-acting psychostimulants in pediatric attention-deficit/hyperactivity disorder. Postgraduate medicine. 2008 Sep:120(3):69-88. doi: 10.3810/pgm.2008.09.1909. Epub [PubMed PMID: 18824827]

[19]

Cody JT, Schwarzhoff R. Fluorescence polarization immunoassay detection of amphetamine, methamphetamine, and illicit amphetamine analogues. Journal of analytical toxicology. 1993 Jan-Feb:17(1):23-33 [PubMed PMID: 8429622]

[20]

Spiller HA, Ryan ML, Weston RG, Jansen J. Clinical experience with and analytical confirmation of "bath salts" and "legal highs" (synthetic cathinones) in the United States. Clinical toxicology (Philadelphia, Pa.). 2011 Jul:49(6):499-505. doi: 10.3109/15563650.2011.590812. Epub [PubMed PMID: 21824061]

[21]

DePriest AZ, Knight JL, Doering PL, Black DL. Pseudoephedrine and false-positive immunoassay urine drug tests for amphetamine. Pharmacotherapy. 2013 May:33(5):e88-9. doi: 10.1002/phar.1216. Epub 2012 Oct 12 [PubMed PMID: 23065913]

[22]

Bedussi F, Acerbis E, Noseda R, Demagistri D, Zamprogno E, Ceschi A. False-positive urine screen test for MDMA in a patient exposed to mebeverine. British journal of clinical pharmacology. 2021 May:87(5):2397-2398. doi: 10.1111/bcp.14624. Epub 2020 Nov 16 [PubMed PMID: 33200465]

[23]

Leclercq M, Soichot M, Delhotal-Landes B, Bourgogne E, Gourlain H, Mégarbane B, Labat L. False positive amphetamines and 3,4-methylenedioxymethamphetamine immunoassays in the presence of metoprolol-two cases reported in clinical toxicology. Journal of analytical toxicology. 2020 Mar 7:44(2):200-205. doi: 10.1093/jat/bkz051. Epub [PubMed PMID: 31384953]

Level 3 (low-level) evidence

[24]

Wijngaard R, Parra-Robert M, Marés L, Escalante A, Salgado E, González-de-la-Presa B, To-Figueras J, Brunet M. Tetracaine from urethral ointment causes false positive amphetamine results by immunoassay. Clinical toxicology (Philadelphia, Pa.). 2021 Jun:59(6):500-505. doi: 10.1080/15563650.2020.1834114. Epub 2020 Oct 28 [PubMed PMID: 33112680]

[25]

Vorce SP, Holler JM, Cawrse BM, Magluilo J Jr. Dimethylamylamine: a drug causing positive immunoassay results for amphetamines. Journal of analytical toxicology. 2011 Apr:35(3):183-7 [PubMed PMID: 21439156]

[26]

Kaplan J, Shah P, Faley B, Siegel ME. Case Reports of Aripiprazole Causing False-Positive Urine Amphetamine Drug Screens in Children. Pediatrics. 2015 Dec:136(6):e1625-8. doi: 10.1542/peds.2014-3333. Epub 2015 Nov 2 [PubMed PMID: 26527556]

Level 3 (low-level) evidence

[27]

Liu L, Wheeler SE, Rymer JA, Lower D, Zona J, Peck Palmer OM, Tamama K. Ranitidine interference with standard amphetamine immunoassay. Clinica chimica acta; international journal of clinical chemistry. 2015 Jan 1:438():307-8. doi: 10.1016/j.cca.2014.09.012. Epub 2014 Sep 19 [PubMed PMID: 25242739]

[28]

Pisani F, Oteri G, Costa C, Di Raimondo G, Di Perri R. Effects of psychotropic drugs on seizure threshold. Drug safety. 2002:25(2):91-110 [PubMed PMID: 11888352]

[29]

Kreuzer P, Landgrebe M, Wittmann M, Schecklmann M, Poeppl TB, Hajak G, Langguth B. Hypothermia associated with antipsychotic drug use: a clinical case series and review of current literature. Journal of clinical pharmacology. 2012 Jul:52(7):1090-7. doi: 10.1177/0091270011409233. Epub 2011 Sep 28 [PubMed PMID: 21956608]

Level 2 (mid-level) evidence

[30]

Shiloh R, Schapir L, Bar-Ziv D, Stryjer R, Konas S, Louis R, Hermesh H, Munitz H, Weizman A, Valevski A. Association between corneal temperature and mental status of treatment-resistant schizophrenia inpatients. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 2009 Sep:19(9):654-8. doi: 10.1016/j.euroneuro.2009.04.010. Epub 2009 Jun 2 [PubMed PMID: 19493658]

[31]

Evers SS, Calcagnoli F, van Dijk G, Scheurink AJ. Olanzapine causes hypothermia, inactivity, a deranged feeding pattern and weight gain in female Wistar rats. Pharmacology, biochemistry, and behavior. 2010 Nov:97(1):163-9. doi: 10.1016/j.pbb.2010.05.029. Epub 2010 Jun 4 [PubMed PMID: 20570692]

[32]

Ray LA, Bujarski S, Courtney KE, Moallem NR, Lunny K, Roche D, Leventhal AM, Shoptaw S, Heinzerling K, London ED, Miotto K. The Effects of Naltrexone on Subjective Response to Methamphetamine in a Clinical Sample: a Double-Blind, Placebo-Controlled Laboratory Study. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2015 Sep:40(10):2347-56. doi: 10.1038/npp.2015.83. Epub 2015 Mar 24 [PubMed PMID: 25801501]

Level 1 (high-level) evidence

[33]

Moerke MJ, Banks ML, Cheng K, Rice KC, Negus SS. Maintenance on naltrexone+amphetamine decreases cocaine-vs.-food choice in male rhesus monkeys. Drug and alcohol dependence. 2017 Dec 1:181():85-93. doi: 10.1016/j.drugalcdep.2017.09.020. Epub 2017 Oct 13 [PubMed PMID: 29040826]

[34]

Sakloth F, Negus SS. Naltrexone maintenance fails to alter amphetamine effects on intracranial self-stimulation in rats. Experimental and clinical psychopharmacology. 2018 Apr:26(2):195-204. doi: 10.1037/pha0000183. Epub 2018 Mar 12 [PubMed PMID: 29528663]

[35]

Guterstam J, Jayaram-Lindström N, Berrebi J, Petrovic P, Ingvar M, Fransson P, Franck J. Cue reactivity and opioid blockade in amphetamine dependence: A randomized, controlled fMRI study. Drug and alcohol dependence. 2018 Oct 1:191():91-97. doi: 10.1016/j.drugalcdep.2018.06.023. Epub 2018 Jul 26 [PubMed PMID: 30096639]

Level 1 (high-level) evidence

[36]

Stoops WW, Pike E, Hays LR, Glaser PE, Rush CR. Naltrexone and bupropion, alone or combined, do not alter the reinforcing effects of intranasal methamphetamine. Pharmacology, biochemistry, and behavior. 2015 Feb:129():45-50. doi: 10.1016/j.pbb.2014.11.018. Epub 2014 Nov 29 [PubMed PMID: 25459104]

[37]

Winsløw F, Hansen NS, Jensen MB. Vertebral Artery Dissection Related to Amphetamine Abuse - A Case Report. Journal of central nervous system disease. 2020:12():1179573520939340. doi: 10.1177/1179573520939340. Epub 2020 Jun 30 [PubMed PMID: 32655281]

Level 3 (low-level) evidence

[38]

Wang AM, Suojanen JN, Colucci VM, Rumbaugh CL, Hollenberg NK. Cocaine- and methamphetamine-induced acute cerebral vasospasm: an angiographic study in rabbits. AJNR. American journal of neuroradiology. 1990 Nov-Dec:11(6):1141-6 [PubMed PMID: 2124040]

[39]

Buxton N, McConachie NS. Amphetamine abuse and intracranial haemorrhage. Journal of the Royal Society of Medicine. 2000 Sep:93(9):472-7 [PubMed PMID: 11089483]

[40]

Goyal P, Sethi P, Sharma S. Prevalence of recreational substance use in patients presenting with seizures to a tertiary care hospital. Epilepsy & behavior : E&B. 2021 Dec:125():108419. doi: 10.1016/j.yebeh.2021.108419. Epub 2021 Nov 24 [PubMed PMID: 34837845]

[41]

Madea B, Ruppel E, Prangenberg J, Krämer M, Doberentz E. Expression of heat shock proteins 27, 60, and 70 in amphetamine and cocaine associated deaths. Forensic science international. 2021 Dec:329():111088. doi: 10.1016/j.forsciint.2021.111088. Epub 2021 Oct 30 [PubMed PMID: 34773820]

[42]

Green AR, Cross AJ, Goodwin GM. Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or "Ecstasy"). Psychopharmacology. 1995 Jun:119(3):247-60 [PubMed PMID: 7675958]

[43]

O'Connor AD, Rusyniak DE, Bruno A. Cerebrovascular and cardiovascular complications of alcohol and sympathomimetic drug abuse. The Medical clinics of North America. 2005 Nov:89(6):1343-58 [PubMed PMID: 16227066]

[44]

Pozoga J, Snopek G, Dabrowski M. [Acute coronary syndrome after amphetamine use in a young male with myocardial bridging--a case report]. Kardiologia polska. 2005 Apr:62(4):381-2 [PubMed PMID: 15928743]

Level 3 (low-level) evidence

[45]

Kueh SA, Gabriel RS, Lund M, Sutton T, Bradley J, Kerr AJ, Looi JL. Clinical Characteristics and Outcomes of Patients with Amphetamine-Associated Cardiomyopathy in South Auckland, New Zealand. Heart, lung & circulation. 2016 Nov:25(11):1087-1093. doi: 10.1016/j.hlc.2016.03.008. Epub 2016 Apr 20 [PubMed PMID: 27185546]

[46]

Jacobs W. Fatal amphetamine-associated cardiotoxicity and its medicolegal implications. The American journal of forensic medicine and pathology. 2006 Jun:27(2):156-60 [PubMed PMID: 16738435]

[47]

Ayme-Dietrich E, Lawson R, Côté F, de Tapia C, Da Silva S, Ebel C, Hechler B, Gachet C, Guyonnet J, Rouillard H, Stoltz J, Quentin E, Banas S, Daubeuf F, Frossard N, Gasser B, Mazzucotelli JP, Hermine O, Maroteaux L, Monassier L. The role of 5-HT(2B) receptors in mitral valvulopathy: bone marrow mobilization of endothelial progenitors. British journal of pharmacology. 2017 Nov:174(22):4123-4139. doi: 10.1111/bph.13981. Epub 2017 Oct 15 [PubMed PMID: 28806488]

[48]

Naqvi TZ, Gross SB. Anorexigen-induced cardiac valvulopathy and female gender. Current women's health reports. 2003 Apr:3(2):116-25 [PubMed PMID: 12628081]

[49]

Westover AN, Nakonezny PA. Aortic dissection in young adults who abuse amphetamines. American heart journal. 2010 Aug:160(2):315-21. doi: 10.1016/j.ahj.2010.05.021. Epub [PubMed PMID: 20691838]

[50]

Swalwell CI, Davis GG. Methamphetamine as a risk factor for acute aortic dissection. Journal of forensic sciences. 1999 Jan:44(1):23-6 [PubMed PMID: 9987866]

[51]

Hu HY, Wei SY, Pan CH. Rhabdomyolysis observed at forensic autopsy: a series of 52 cases. Forensic science, medicine, and pathology. 2018 Dec:14(4):424-431. doi: 10.1007/s12024-018-0003-x. Epub 2018 Jul 28 [PubMed PMID: 30056625]

Level 3 (low-level) evidence

[52]

Farah R, Farah R. Ecstasy (3,4-methylenedioxymethamphetamine)-induced inappropriate antidiuretic hormone secretion. Pediatric emergency care. 2008 Sep:24(9):615-7. doi: 10.1097/PEC.0b013e3181850c91. Epub [PubMed PMID: 18797371]

[53]

Panikkath R, Panikkath D. Amphetamine-related ischemic colitis causing gastrointestinal bleeding. Proceedings (Baylor University. Medical Center). 2016 Jul:29(3):325-6 [PubMed PMID: 27365888]

[54]

Green PA, Battersby C, Heath RM, McCrossan L. A fatal case of amphetamine induced ischaemic colitis. Annals of the Royal College of Surgeons of England. 2017 Sep:99(7):e200-e201. doi: 10.1308/rcsann.2016.0350. Epub [PubMed PMID: 28853604]

Level 3 (low-level) evidence

[55]

Kurtz B, Alshoubi A, Nguyen K, Gehres E. Methamphetamine-Induced Bowel Ischemia in a 50-Year-Old Male. Case reports in critical care. 2022:2022():9690034. doi: 10.1155/2022/9690034. Epub 2022 Apr 5 [PubMed PMID: 35402052]

Level 3 (low-level) evidence

[56]

Attaran H. Fatal Small Intestinal Ischemia Due to Methamphetamine Intoxication: Report of a Case With Autopsy Results. Acta medica Iranica. 2017 May:55(5):344-347 [PubMed PMID: 28724276]

Level 3 (low-level) evidence

[57]

Medhus S, Rognli EB, Gossop M, Holm B, Mørland J, Bramness JG. Amphetamine-induced psychosis: Transition to schizophrenia and mortality in a small prospective sample. The American journal on addictions. 2015 Oct:24(7):586-9. doi: 10.1111/ajad.12274. Epub 2015 Sep 1 [PubMed PMID: 26332037]

[58]

Ginovart N, Farde L, Halldin C, Swahn CG. Changes in striatal D2-receptor density following chronic treatment with amphetamine as assessed with PET in nonhuman primates. Synapse (New York, N.Y.). 1999 Feb:31(2):154-62 [PubMed PMID: 10024013]

[59]

Boileau I, Dagher A, Leyton M, Gunn RN, Baker GB, Diksic M, Benkelfat C. Modeling sensitization to stimulants in humans: an [11C]raclopride/positron emission tomography study in healthy men. Archives of general psychiatry. 2006 Dec:63(12):1386-95 [PubMed PMID: 17146013]

[60]

Chen PI, Cao A, Miyagawa K, Tojais NF, Hennigs JK, Li CG, Sweeney NM, Inglis AS, Wang L, Li D, Ye M, Feldman BJ, Rabinovitch M. Amphetamines promote mitochondrial dysfunction and DNA damage in pulmonary hypertension. JCI insight. 2017 Jan 26:2(2):e90427. doi: 10.1172/jci.insight.90427. Epub 2017 Jan 26 [PubMed PMID: 28138562]

[61]

van Wolferen SA, Vonk Noordegraaf A, Boonstra A, Postmus PE. [Pulmonary arterial hypertension due to the use of amphetamines as drugs or doping]. Nederlands tijdschrift voor geneeskunde. 2005 Jun 4:149(23):1283-8 [PubMed PMID: 15960135]

[62]

Zamanian RT, Hedlin H, Greuenwald P, Wilson DM, Segal JI, Jorden M, Kudelko K, Liu J, Hsi A, Rupp A, Sweatt AJ, Tuder R, Berry GJ, Rabinovitch M, Doyle RL, de Jesus Perez V, Kawut SM. Features and Outcomes of Methamphetamine-associated Pulmonary Arterial Hypertension. American journal of respiratory and critical care medicine. 2018 Mar 15:197(6):788-800. doi: 10.1164/rccm.201705-0943OC. Epub [PubMed PMID: 28934596]

[63]

Seiden LS, Sabol KE, Ricaurte GA. Amphetamine: effects on catecholamine systems and behavior. Annual review of pharmacology and toxicology. 1993:33():639-77 [PubMed PMID: 8494354]

[64]

Ross LJ, Wilson M, Banks M, Rezannah F, Daglish M. Prevalence of malnutrition and nutritional risk factors in patients undergoing alcohol and drug treatment. Nutrition (Burbank, Los Angeles County, Calif.). 2012 Jul:28(7-8):738-43. doi: 10.1016/j.nut.2011.11.003. Epub 2012 Feb 21 [PubMed PMID: 22356728]

[65]

Laslett AM, Dietze P, Dwyer R. The oral health of street-recruited injecting drug users: prevalence and correlates of problems. Addiction (Abingdon, England). 2008 Nov:103(11):1821-5. doi: 10.1111/j.1360-0443.2008.02339.x. Epub [PubMed PMID: 19032532]

[66]

Smart RJ, Rosenberg M. Methamphetamine abuse: medical and dental considerations. Journal of the Massachusetts Dental Society. 2005 Summer:54(2):44-6, 48-9 [PubMed PMID: 16149403]

[67]

Yeh TC, Lin YC, Chen LF, Chiang CP, Mao WC, Chang HA, Kao YC, Tzeng NS. Aripiprazole treatment in a case of amphetamine-induced delusional infestation. The Australian and New Zealand journal of psychiatry. 2014 Jul:48(7):681-2. doi: 10.1177/0004867414525849. Epub 2014 Feb 21 [PubMed PMID: 24563196]

Level 3 (low-level) evidence

[68]

Rhee KJ, Albertson TE, Douglas JC. Choreoathetoid disorder associated with amphetamine-like drugs. The American journal of emergency medicine. 1988 Mar:6(2):131-3 [PubMed PMID: 3355623]

[69]

Lundh H, Tunving K. An extrapyramidal choreiform syndrome caused by amphetamine addiction. Journal of neurology, neurosurgery, and psychiatry. 1981 Aug:44(8):728-30 [PubMed PMID: 7299411]